Article Per Year (5 Year)
p-Index From 2021 - 2026
2.096
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences SAINS MEDIKA : JURNAL KEDOKTERAN DAN KESEHATAN Microbiology Indonesia Science and Technology Indonesia Manuju : Malahayati Nursing Journal Eksakta : Berkala Ilmiah Bidang MIPA Jurnal Biomedika dan Kesehatan East Asian Journal of Multidisciplinary Research (EAJMR) Makara Journal of Science Indonesian Journal of Biomedicine and Clinical Sciences
SJATHA, FITHRIYAH
Departement Of Microbiology, Faculty Of Medicine, Universitas Indonesia, Jakarta, DKI Jakarta, Indonesia
Agriculture, Biological Sciences & Forestry Astronomy Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Decision Sciences, Operations Research & Management Earth & Planetary Sciences Economics, Econometrics & Finance Education Energy Engineering Environmental Science Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Materials Science & Nanotechnology Mathematics Mechanical Engineering Medicine & Pharmacology Neuroscience Nursing Physics Public Health

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 13 Documents
Search

 1   2 
Risiko Reaktivasi Tuberkulosis Laten pada Terapi COVID-19 Abas, Ghina Mutiara; Sjatha, Fithriyah; Rosana, Yeva
Jurnal Biomedika dan Kesehatan Vol 6 No 3 (2023)
Publisher : Fakultas Kedokteran Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/JBiomedKes.2023.v6.363-372

Abstract

The high mortality rate among COVID-19 patients in the acute respiratory distress syndrome (ARDS) phase led to the administration of immunosuppressive drugs. Corticosteroids could block inflammation caused by cytokine storm, and prevent pneumonia, edema, fibrosis, and ARDS. Even though it was believed to have beneficial effects, corticosteroids can suppress T CD4+ and CD8+ cell-mediated immunity reaction through decreased IFNγ production thus leading to reactivation of latent Tuberculosis (LTBI). Therefore, the usage of corticosteroids in the ARDS phase of COVID-19 patients should be carefully given; pre-screening of LTBI may be done to avoid Tuberculosis reactivation.
The Effect of Probiotic Supplementation in Cholestasis Liver Disease: A Systematic Review of Animal Studies Azizah, Nur; Oswari, Hanifah; Sjatha, Fithriyah
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 25 No. 03 (2024): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464)
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol25-iss03/533

Abstract

Gut microbiome is essential in maintaining metabolism, gut barrier homeostasis, inflammation, and hematopoiesis. Several factors affect gut microbiome composition, including genetics, lifestyle, external factors, and disease. Cholestasis liver disease promotes gut dysbiosis via abnormal bile production or flow to the intestine and disrupts the gut microbiome. This condition leads to intestinal leakage, which enables bacterial and endotoxin translocation to the liver through the portal vein. Bacterial translocation promotes inflammatory responses, which worsen liver damage in cholestasis. Moreover, probiotic supplementation in other diseases has been shown to preserve gut microbiome composition. While such studies have documented probiotics' beneficial effects, no adequate clinical trials support probiotics' potency as a cholestasis treatment. Hence, this systematic review aims to provide an in-depth analysis of probiotic supplementation as a therapy for cholestasis liver disease in animal models. The search strategies were conducted based on PRISMA methodologies based on various academic literature. The selected studies have shown improvements in bile acid metabolism, microbiota-gut-liver axis, gut epithelium integrity, liver damage and inflammation response, and liver fibrosis progression, which need to be confirmed in human clinical trials.
Development of Vaccine Candidates Against Mycobacterium Tuberculosis in 2019-2023 Adiyaksa, Jongga; Sjatha, Fithriyah
Malahayati Nursing Journal Vol 6, No 5 (2024): Volume 6 Nomor 5 2024
Publisher : Universitas Malahayati Lampung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/mnj.v6i5.14396

Abstract

ABSTRACT With extensive use of the Bacillus Calmette–Guérin (BCG) vaccine, the global prevalence of Mycobacterium tuberculosis (MTB) remains. A number of vaccines proposed to cure and prevent tuberculosis (TB) infection are undergoing various stages of clinical trials. Although vaccine production is progressing, more attention is needed. A number of TB vaccines are currently undergoing clinical trials, most of which rely on a combination of proteins and/or adjuvants or recombinant viral vectors specific for MTB antigens. We tried to cover the range of TB vaccines in this study by analyzing their composition, the immunological responses they elicit, and the stages of clinical trials. To find out the Development Of Prospective Vaccines Against Mycobacterium Tuberculosis. This research uses a literature review, between August 2023 and November 2023, the authors of this literature review checked PubMed, Science Direct, Google Scholar, and other databases containing research findings or scientific articles. Only studies that met the above search criteria were included in the systematic review. Many recently developed tuberculosis vaccines are reportedly in the final stages of clinical trials, where they have significantly strengthened the immune system and even produced protection against the host. Immunization produced by vaccines that have successfully passed the initial stages of clinical trials is safe and effective, and can even surpass BCG in terms of immunity.  Based on the description above, it can be concluded that many recently developed tuberculosis vaccines are reported to be in the final stages of clinical trials, where they have significantly strengthened the immune system and even produced protection against the host. Immunization produced by vaccines that have successfully passed the initial stages of clinical trials is safe and effective, and can even surpass BCG in terms of immunity. With the development of new TB vaccines that strengthen the body's immunity and create effective delivery mechanisms, hopes for TB treatment and prevention are increasing. The development of vaccine effects can be facilitated, in part, through the use of effective delivery mechanisms, which have also been used in TB vaccines. Keywords: Tuberculosis, Vaccine, Bacteria, Mycobacterium Tuberculosis, BCG
Co-Authors . Andriansjah Abas, Ghina Mutiara Adiyaksa, Jongga Andi Yasmon Anis Karuniawati Beti Ernawati Dewi Clara Riski Amanda Engel, Yulia Fadilah Fadilah, Fadilah Hanifah Oswari Mardhiyah, Azzahrah Khairunnisa Marintan, Marchia Marthalena Mifa Nurfadilah Muhamad Rizqy Fadhillah Nur Azizah Nur Azizah Nurani, Dita Arifa Nurul Gusti Khatimah OKTIVIA CHANDRA MUSTIKA Purnomosidi, Muhammad Abhi Rida Tiffarent Rizky Clarinta Putri Rosa, Yulia Rosdiana Irawati Sariman Sariman Supardi, Lulut Azmi Tjahjani Mirawati Sudiro Tjampakasari, Conny Riana Windi Muziasari Yeva Rosana Yulia Rosa Saharman Yuni Krisyuningsih Krisnandi, Yuni Krisyuningsih